Stock vs Stock Comparison

Aurinia Pharmaceuticals Inc. vs Abbott Laboratories

AUPH wins the Tale of the Tape 8–1.

AUPH
ABT$86.99

🏆 Tale of the Tape

81
AUPHABT
101.5%Profitability (Net Margin)14.7%
6.8xValuation (P/E)24.0x
14.2%Efficiency (ROIC)10.1%
7/9Health (Piotroski F)5/9
6.9Safety (Altman Z)4.9
20.4%Growth (Rev YoY)5.7%
Risk (Sharpe 1Y)-1.05
0.29xBalance Sheet (D/E)0.64x
7.30%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricAUPHABT
Market Cap$1.9B$149.1B
P/E Ratio6.8x24.0x
Forward P/E16.9x14.1x
P/B3.21x2.86x
Dividend Yield2.94%
Beta1.590.65

Quantitative Metrics

MetricAUPHABT
DCF Fair Value$21.72$57.20
DCF Upside-43.2%
Piotroski F7/95/9
Altman Z6.944.87
Beneish M8.64-2.53
FCF Yield7.30%4.21%
Net Debt/EBITDA-0.2x0.1x
ROIC14.2%10.1%
WACC14.2%9.4%
ROIC – WACC0.0pp0.7pp
Gross Margin88.5%56.4%
Net Margin101.5%14.7%
Rev Growth YoY20.4%5.7%
Sharpe (1Y)-1.05
Max Drawdown 3Y
FCF Payout Ratio56%

AUPH Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

AUPH found in:

GWX0.17%
VFMO0.12%
VFQY0.11%
VHT0.03%
SPDW0.00%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

AUPH vs ABT: Head-to-Head Analysis

Aurinia Pharmaceuticals Inc. (AUPH) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, AUPH leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, AUPH generates a return on invested capital (ROIC) of 14.2% compared to ABT's 10.1%. This suggests AUPH is more effective at deploying capital to generate shareholder returns.

AUPH appears in 5 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, AUPH or ABT?

Our quantitative analysis compares AUPH and ABT across nine fundamental dimensions. AUPH wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are AUPH and ABT correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.